VBL Therapeutics, Ltd. (VBLT)

Oncology Corporate Profile

Stock Performance

3.2300
0.0300

3 Month Stock History Chart

HQ Location

6 Jonathan Netanyahu St.
Or Yehuda, Israel 60376

Company Description

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company's lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer.

Website: http://www.vblrx.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
VB-111anti angiogenic agentGlioblastoma Multiforme (GBM)III
VB-111anti angiogenic agentOvarian cancerII
VB-111anti angiogenic agentThyroid cancerII
VB-111anti angiogenic agentVarious cancer typesI

View additional information on product candidates here »

Source: http://www.vblrx.com

Recent News Headlines

8/21/2017 06:23 am

8/21/2017 06:23 am

8/21/2017 06:23 am

8/16/2017 06:20 am

8/16/2017 06:20 am

8/16/2017 06:20 am

8/15/2017 06:20 am

8/15/2017 06:20 am

8/14/2017 06:20 pm

8/14/2017 12:20 am

8/13/2017 12:20 am

8/1/2017 06:20 pm

7/24/2017 12:20 am

7/2/2017 12:20 am

6/19/2017 06:20 am

6/19/2017 06:20 am

6/15/2017 12:20 am

6/15/2017 12:20 am

6/14/2017 06:20 am

6/14/2017 06:20 am

6/14/2017 06:20 am

6/8/2017 12:20 am

6/5/2017 06:20 am

5/15/2017 06:19 am

5/15/2017 12:19 am